Selective Serotonin Reuptake Inhibitor-Treatment Does Not Show Beneficial Effects on Cognition or Amyloid Burden in Cognitively Impaired and Cognitively Normal Subjects
2022-06-23 | journal article; research paper. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Selective Serotonin Reuptake Inhibitor-Treatment Does Not Show Beneficial Effects on Cognition or Amyloid Burden in Cognitively Impaired and Cognitively Normal Subjects
Bouter, Y. & Bouter, C. (2022)
Frontiers in Aging Neuroscience, 14 art. 883256. DOI: https://doi.org/10.3389/fnagi.2022.883256
Documents & Media
fnagi-14-883256.pdf2.16 MBAdobe PDFfnagi-14-883256-g001.tif60.38 kBTIFFfnagi-14-883256-g002.tif143.95 kBTIFFfnagi-14-883256-g003.tif98.72 kBTIFFfnagi-14-883256-g004.tif203.96 kBTIFFfnagi-14-883256-g005.tif94.6 kBTIFFfnagi-14-883256-g006.tif92.34 kBTIFF
Details
- Authors
- Bouter, Yvonne ; Bouter, Caroline
- Abstract
- Preclinical studies indicate that selective serotonin reuptake inhibitors (SSRI) have beneficial effects on Alzheimer-related pathologies. Therefore, the aim of this study was to evaluate the influence of SSRI-treatment on amyloid burden in 18F-Florbetapir-positron emission tomography (PET) and on cognition in cognitively normal and cognitively impaired subjects. We included n = 755 cognitively impaired and n = 394 cognitively normal participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) that underwent at least one 18F-Florbetapir-PET. Standardized uptake ratios (SUVR) and the Alzheimer Disease Assessment Scale-cognitive subscale (ADAS) scores as well as follow-up results were compared between subgroups with a history of SSRI-treatment (SSRI+) and without SSRI-treatment (SSRI-) as well as in subgroups of SSRI+/Depression+ and SSRI+/Depression- and SSRI-/Depression+ and SSRI-/Depression-. 18F-Florbetapir-PET did not show significant differences of SUVR between the SSRI+ and SSRI- groups in both, cognitively impaired and cognitively normal participants. There were no differences in subgroups of SSRI+/Depression+ and SSRI+/Depression- and SSRI-/Depression+ and SSRI-/Depression-. However, SUVR showed a dose-dependent inverse correlation to the duration of medication in cognitively normal and in cognitively impaired patients. SRRI-treatment did not show an effect on ADAS scores. Furthermore, there was no effect on follow-up SUVR or on follow-up ADAS scores. Overall, SSRI-treatment did not show beneficial effects on amyloid load nor on cognition.
- Issue Date
- 23-June-2022
- Journal
- Frontiers in Aging Neuroscience
- eISSN
- 1663-4365
- Language
- English
- Sponsor
- Open-Access-Publikationsfonds 2022